Mergers & Acquisitions - Actavis

Filter

Current filters:

Actavis

Popular Filters

46 to 70 of 916 results

Verastem acquires cancer stem cell inhibitor VS-4718 rights from Poniard

27-02-2014

US drug developer Verastem has acquired the license to VS-4718, which targets cancer stem cells, held…

BiotechnologyMergers & AcquisitionsOncologyPoniard PharmaceuticalsVerastemVS-4718

Way clear for Bayer to complete Algeta acquisition

26-02-2014

The way is now clear for Germany’s Bayer to acquire Norwegian pharmaceutical company Algeta, under…

AlgetaBayerMergers & AcquisitionsOncologyPharmaceuticalXofigo

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Indian drugmakers readying for next “Patent cliff”

24-02-2014

The strategic drug reviews, as well as mergers and acquisitions – such as Actavis buying out Forest…

Asia-PacificGenericsIndiaMergers & AcquisitionsPatentsPharmaceuticalRegulation

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

Actavis net revenue rise 59% beats forecasts; non-GAAP EPS rises 99%

20-02-2014

Acquisitive Ireland-headquartered generics major Actavis says that net revenue leapt 59% to $2.779 billion…

ActavisFinancialGenerics

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Nestle takes full control of Galderma Pharma

19-02-2014

The boards of Switzerland-based Nestle, the world’s largest food company, and French cosmetics firm…

DermatologicalsGaldermaMergers & AcquisitionsNestlePharmaceutical

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion

18-02-2014

After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

ProductLife Group expands German operations with acquisition

18-02-2014

UK life sciences outsourcing and consulting services specialist ProductLife Group (PLG) has announced…

Kohne PharmaMergers & AcquisitionsPharmaceuticalProductLife Group

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

17-02-2014

Privately-held USA-based Prothelia and the University of Nevada, Reno, have entered into strategic agreements…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceuticalProtheliaRare diseasesResearch

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Mallinckrodt to buy Cadence Pharma for around $1.3 billion

12-02-2014

Ireland-headquartered specialty drugmaker Mallinckrodt, spun off by Covidien last year, has entered into…

Cadence PharmaceuticalsMallinckrodtMergers & AcquisitionsOfirmevPharmaceutical

Increasing investment in Latin American pharma market

Increasing investment in Latin American pharma market

12-02-2014

Around $12.7 billion has been invested in Latin America’s pharmaceutical market through mergers and…

ArgentinaBrazilChileEcuadorFinancialMergers & AcquisitionsPharmaceuticalSouth America

Mast Therapeutics to acquire Aires Pharma

10-02-2014

USA-based Mast Therapeutics has entered into a definitive agreement to acquire privately-held clinical-stage…

AIR001Aires PharmaceuticalsMast TherapeuticsMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Adcock Ingram and CFR Pharma call off merger

Adcock Ingram and CFR Pharma call off merger

10-02-2014

South Africa’s Adcock Ingram and Chile’s largest drugmaker CFR Pharmaceuticals have issued a joint…

Adcock IngramBidvestCFR PharmaceuticalsMergers & AcquisitionsPharmaceuticalRest of the WorldSouth Africa

Pharma M&A momentum expected to continue into 2014, says PwC

Pharma M&A momentum expected to continue into 2014, says PwC

10-02-2014

Pharmaceutical and life sciences (PLS) merger and acquisition (M&A) volume and value increased in the…

Mergers & AcquisitionsPharmaceutical

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

07-02-2014

Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

Actavis confirms generic Treanda patent challenge

Actavis confirms generic Treanda patent challenge

04-02-2014

US generics drug major Actavis confirms that it has filed an Abbreviated New Drug Application with the…

ActavisCephalonGenericsNorth AmericaOncologyPatentsTeva Pharmaceutical IndustriesTreandaUSA

Valeant spending $475 million to boost dermatology portfolio

Valeant spending $475 million to boost dermatology portfolio

03-02-2014

Acquisitive Canadian drugmaker Valeant Pharmaceuticals International has entered into a definitive agreement…

DermatologicalsMergers & AcquisitionsPharmaceuticalPreCision DermatologyValeant Pharmaceuticals

Actavis refocuses global business structure; reiterates 2014 outlook

Actavis refocuses global business structure; reiterates 2014 outlook

01-02-2014

US generics major Actavis, which now has its headquarters in Ireland, has announced a realignment of…

ActavisBoardroomFinancialGenerics

46 to 70 of 916 results

Back to top